Perinatal Depression & Anxiety (PDA) and Maternal Gut Microbiome

Perinatal Depression Clinical Trial

Official title:

Targeting Maternal Gut to Improve Mental Health Outcomes-- A Feasibility Pilot Clinical Trial

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06074250
• Other study ID #: CCNMREB049
• Status: Not yet recruiting
• Phase: Phase 2/Phase 3
• Start date: January 2024
• Est. completion date: March 2028

Study information

• Verified date: August 2023
• Source: The Canadian College of Naturopathic Medicine
• Contact: Neda Ebrahimi, PhD
• Phone: 416-498-1255
• Email: nebrahimi[@]ccnm.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Perinatal depression and anxiety (PDA) are the leading causes of maternal mortality in developed countries. Women with a history of depression have a 20 fold higher risk of PDA at subsequent pregnancies. The adverse outcomes extend beyond maternal well-being to long-term deficits in children and families. The gut-brain axis is a newly recognized key player in mental health disorders. Specifically, the microbial composition of the gut along with their metabolites are directly involved in disease onset and course. Recent clinical studies have identified diet as the most powerful environmental factor in manipulating gut microbiome. Given vulnerability and resistance of pregnant women to pharmacotherapy, particularly in those with a predisposition to mood disorders, as well as pregnant women's high motivation and commitment to improving gestational diet, a dietary/supplemental intervention to 'optimize' gut microbiome, is a favored approach in disease management. The study investigators aim to exploit microbial responsiveness to diet together with this maternal motivation, to alter the risk and severity of a universal public health concern that has dire and long-term consequences for new moms and their children.

The investigators of this trial, will first study the challenges in pursuing a study aimed at changing the microbiome of pregnant women with a history of mood disorders. Pregnant women in their second trimester will be recruited. Each will be assigned or randomized to one of four groups that will use a combination of diet, supplementation with probiotics, fish oil or no intervention. Each participant will meet with the study team virtually every 3 months until 1 year after delivery. At each study visit participants will be required to complete some questionnaires about their food intake, mood, and other health related measures and will provide a stool sample using the stool collection kits provided.

The findings from this study will help strategize for a larger study that will allow for comparison of the effects of diet, and/or supplementation with Omega-3 Fatty Acids (O3FA) and probiotics on the microbiome and the onset and severity of PDA.

Description:

Pregnant women with a history of anxiety and/or depression & currently stable, will be recruited and randomized or assigned to one of four study groups. A total of 100 will be recruited and required to complete six study visits, one every 3 months. At each visit, data on dietary intake, mental health scores, and stool samples will be collected using appropriate tools. All visits will be completed virtually, unless participants need in-person follow-ups.

The final visit is expected to occur between 9-12 months after delivery. The primary outcome for this study is feasibility, measured by: recruiting the targeted number of participant within the anticipated timeframe, and completion of at least 4 of the 6 visits by each participant.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 100
• Est. completion date: March 2028
• Est. primary completion date: December 2027
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 43 Years

Eligibility

Inclusion Criteria

• Women 18-43 years old

• 12-35 weeks of gestation

• Non-smoker/alcohol/recreational drug user

• Financially stable

• Clinical diagnosis of lifetime depression/anxiety or PDA but currently well

• English speaking

Exclusion Criteria:

• BMI=30

• Low income (unable to afford basic daily needs (i.e., shelter, food, etc.)

• Diagnosis with other major mental health disorders (Bipolar, Psychosis, Addiction, Schizophrenia);

• Diagnosis with other severe medical conditions (i.e. epilepsy, neurological disorders, etc.)

• Allergies to fish oils/ingredients in supplements

• Conditions that require repeated/chronic antibiotic usage

• Having a child with significant mental/physical disability

• Single mothers without any kind of family support,

• Cigarette, alcohol and recreational drug users

• Women unwilling to switch to study product(s)

• Multiparous women with young children (i.e. one or more children less than 4 years of age at the time of delivery)

• Non-English Readers/Speakers

Related Conditions & MeSH terms

• Asphyxia Neonatorum
• Depression
• Depressive Disorder
• Perinatal Depression

Intervention

Dietary Supplement:
• Fish oil
1500mg EPA +1000mg DHA daily
• Probiotics
Combination strain of lactobacillus and bifidobacteria

Behavioral:
• Prebiotics
Dietary consult with follow-up to ensure target fiber intake is met.
• Diet Quality
one time dietary consult at enrollment to discuss strategies to improve overall diet.

Locations

Country	Name	City	State
Canada	Sunnybrook Health Science Center	Toronto	Ontario

Sponsors (3)

Lead Sponsor	Collaborator
The Canadian College of Naturopathic Medicine	Lotte & John Hecht Memorial Foundation, Sunnybrook Health Sciences Centre

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Feasibility of participant recruitment	Time taken to recruit 100 participants in total and successfully randomize/assign 25 participants per study arm.	20 months
Primary	Adherence to Supplement Intake (estimated using unused portion of supplements)	This outcome will be measured by participants' adherence to the prescribed regiments. At each visit the between-study-visit intake of fish oil, probiotics/ placebo will be; estimated by what remains unused in the original boxes/containers	2 years
Primary	Adherence to Supplement Intake (Number of missed doses/week)	Questionnaires detailing intake frequency of the supplements and missed doses will be used in Groups A, B & C, to assess adherence to prescribed regiments	2 years
Primary	Adherence to Dietary Protocol (Using food frequency questionnaire)	Adherence to the dietary protocol in Group A, will be measured at each study visit and in between study visits to ensure the dietary target is met (i.e. the number of daily servings of specific foods are consumed), and to address and document challenges in reaching the targets.	2 years
Primary	Completion of Study visits(Number of studies with completed tasks)	At each visit participants are expected to provide (1)dietary intake using myfitnesspal, (2) Mental health Scores using EPDS and GAD7 scales, (3) one stool sample, and 4)provide update on lifestyle and health status. A study visit will be marked complete, only if all tasks are completed. Our benchmark for success is for at least 4 of the 6 study visits to be completed by each participants	2 years
Secondary	Study Obstacles (descriptive measures outlining obstacles)	The actual rate of recruitment, intervention acceptability, completion of study tasks (Dietary intake, EPDS, GAD6, stool collection, lifestyle questionnaires), study visit (<6 visits) will be compared to the expected rates at the time of study design. All obstacles to attaining the expected rate, will be documented with descriptive measures.	2 years